PK in Pts With HRPC & Skeletal Metastes

Prostatic Neoplasms Clinical Trial

Official title:

A Phase I, Open-label, Dosimetry, Biodistribution and Pharmacokinetic Study of Alpharadin™ in Patients With Hormone Refractory Prostate Cancer and Skeletal Metastases

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00667537
• Other study ID #: 15302
• Secondary ID: 2006-006101-88BC
• Status: Completed
• Phase: Phase 1
• First received: April 24, 2008
• Last updated: December 11, 2015
• Start date: July 2007
• Est. completion date: December 2008

Study information

• Verified date: December 2015
• Source: Bayer
• Contact: n/a
• Is FDA regulated: No
• Health authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency
• Study type: Interventional

Clinical Trial Summary

Primary objective: To investigate the biodistribution, radiation dosimetry, and pharmacokinetics of two separate intravenous (IV) injections of Xofigo (100 kBq/kg body weight [b.w.] [=110 kBq/kg based on the 2015 National Institute of Standards and Technology standardization], 6 weeks apart).

Secondary objectives: To determine the safety of IV injections of Xofigo after two separate injections (6 weeks apart), to evaluate treatment response (antitumour effect in osteoblastic bone metastases) of Xofigo treatment consisting of two injections of activity 100 kBq/kg b.w. (=110 kBq/kg based on the 2015 National Institute of Standards and Technology standardization), 6 weeks apart and to evaluate long term radiation toxicity and to collect survival data at 6 and 12 months after the first injection

Recruitment information / eligibility

• Status: Completed
• Enrollment: 6
• Est. completion date: December 2008
• Est. primary completion date: December 2008
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically or cytologically confirmed adenocarcinoma of the prostate

• Hormone refractory with evidence of rising prostate-specific antigen (PSA): Subject must be maintained on androgen ablation therapy with luteinizing hormone-releasing hormone agonist or have undergone bilateral orchiectomy

• Serum testosterone level required to be =50 ng/dL

• Subjects who have received prior antiandrogen drug therapy: Flutamide, nilutamide, or cyproterone acetate must have stopped at least 4 weeks prior to study drug administration and progression, as defined by rising PSA as defined below, must have been demonstrated since cessation; bicalutamide must have stopped at least 6 weeks prior to study drug administration and progression, as defined by rising PSA as defined below, must have been demonstrated since cessation

• PSA progression: Progressive rise in PSA, defined as two consecutive increases in PSA documented over a previous reference value (measure 1). The first increase in PSA (measure 2) should occur at a minimum of 1 week from the reference value (measure 1). This increase in PSA should be confirmed (measure 3) after a minimum of 1 week. If the confirmatory PSA value (measure 3) is less than the previous value, the subject will still be eligible provided the next PSA measure (measure 4) is found to be greater than the second PSA value (measure 2)

• Skeletal metastases confirmed by bone scintigraphy within the last 6 weeks

• Performance status: Eastern Co-operative Oncology Group (ECOG) 0-2

• Life expectancy: =6 months

• Laboratory requirements: Neutrophil count =1.5 x 109/L, platelet count =100 x109/L, haemoglobin =95 g/L, total bilirubin level within normal institutional limits, aspartate aminotransferase and alanine aminotransferase =2.5 times upper institutional limit of the normal range, S Creatinine =1.5 times upper institutional limit of the normal range

Exclusion Criteria:

• Has received an investigational drug within 4 weeks prior to the administration of radium-223, or is scheduled to receive one during the treatment and post-treatment period

• Has received chemo-, immunotherapy, or external radiotherapy within the last 4 weeks prior to administration of study drug, or has not recovered from adverse events due to agents administered more than 4 weeks earlier

• More than one regimen of previous cytotoxic chemotherapy

• Has received prior hemibody external radiotherapy

• Has a need for immediate external radiotherapy

• Has received systemic radiotherapy with radium-223, strontium-89, samarium-153, rhenium-186 or rhenium-188 for the treatment of bony metastases within the last year prior to administration of study drug

• Has started treatment with bisphosphonates less than 3 months prior to administration of study drug. Patients are allowed to be on bisphosphonates provided patient is on a stable dose for >/= 12 weeks before administration of study drug

• Patients who are </= 4 weeks (6 weeks for bicalutamide) post withdrawal of antiandrogen therapy

• Patients who have started or stopped systemic steroids, within a week prior to study drug administration, or are expected to be subject to changes in the systemic steroid medication

• Other currently active (relapse within the last 3 years) malignancy (except non-melanoma skin cancer) that are not prostate cancer metastases

• Visceral (e.g. liver, lung) metastases from prostate cancer as assessed by abdominal/ pelvic CT or chest radiograph within six weeks before administration of study drug

• Lymph node metastases with short-axis diameter greater than 2 cm

• Bulky loco-regional disease

• Any other serious illness or medical condition, for example: any uncontrolled infection, any patient who has clinical heart failure severe enough to cause marked limitation of activity, and who is only comfortable at rest; or any patient who has heart failure more severe than this (NYHA Heart Failure Class III or IV), Crohns disease or ulcerative colitis

Study Design

Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science

Related Conditions & MeSH terms

• Prostatic Neoplasms

Intervention

Drug:
• Radium-223 chloride (Xofigo®, BAY88-8223) injection
Sterile, clear and colourless aqueous solution of radium-223 chloride free of endotoxins, for intravenous administration

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Bayer

Country where clinical trial is conducted

United Kingdom, 

References & Publications (4)

Chittenden SJ, Hindorf C, Parker CC, Lewington VJ, Pratt BE, Johnson B, Flux GD. A Phase 1, Open-Label Study of the Biodistribution, Pharmacokinetics, and Dosimetry of 223Ra-Dichloride in Patients with Hormone-Refractory Prostate Cancer and Skeletal Metas — View Citation

Cook G Jr, Parker C, Chua S, Johnson B, Aksnes AK, Lewington VJ. 18F-fluoride PET: changes in uptake as a method to assess response in bone metastases from castrate-resistant prostate cancer patients treated with 223Ra-chloride (Alpharadin). EJNMMI Res. 2 — View Citation

Hindorf C, Chittenden S, Aksnes AK, Parker C, Flux GD. Quantitative imaging of 223Ra-chloride (Alpharadin) for targeted alpha-emitting radionuclide therapy of bone metastases. Nucl Med Commun. 2012 Jul;33(7):726-32. doi: 10.1097/MNM.0b013e328353bb6e. — View Citation

Hobbs RF, Song H, Watchman CJ, Bolch WE, Aksnes AK, Ramdahl T, Flux GD, Sgouros G. A bone marrow toxicity model for ²²³Ra alpha-emitter radiopharmaceutical therapy. Phys Med Biol. 2012 May 21;57(10):3207-22. doi: 10.1088/0031-9155/57/10/3207. Epub 2012 Ma — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Estimation of whole-body retention of radioactivity at each imaging time post-injection		1 week	No
Primary	Estimation of the individual organ uptake/retention of radioactivity at each time-point post injection		1 week	No
Primary	Estimate retention of administered radioactivity in blood		Up to 1 week	No
Primary	Estimation of elimination of radioactivity in urine and faeces		2 days	No
Primary	Calculation of estimated absorbed radiation dose to target organs		1 week	No
Primary	Pharmacokinetics		1 week	No
Secondary	Comparison of the biodistribution and dosimetry after the first and second injection		7 weeks	No
Secondary	Prostate specific antigen (PSA) response	PSA decline, defined as the number of patients with a confirmed =50% reduction in PSA level after treatment with respect to the pre-injection PSA level and the time to PSA progression after PSA response	At baseline, before injections, and at 2 month intervals during the 12 month follow up period	No
Secondary	Survival		6 and 12 months after the first injection	No
Secondary	Adverse events		1 year	Yes
Secondary	Laboratory variables; serum biochemistry and haematology		1 year	Yes
Secondary	Vital signs	Systolic/diastolic blood pressure, respiratory rate, heart rate and body temperature	12 weeks	Yes
Secondary	ECG (12 leads)	Electrocardiogram (12 leads)	12 weeks	Yes
Secondary	Physical examination		1 year	Yes

External Links

•   Click here and search for drug information provided by the FDA.
•   Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.
•   Click here to find information about studies related to Bayer Healthcare products conducted in Europe.
•   Click here to find results for studies related to Bayer Healthcare products.